Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Innovation Pharmaceuticals Inc (IPIX) Message Board

Latest from Leo folks,read bottom to top.Kelt (No

Message Board Public Reply | Private Reply | Keep | Replies (4)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 72446
Posted On: 12/02/2012 1:28:22 PM
Avatar
Posted By: Kelt

Latest from Leo folks,read bottom to top.Kelt


(Note "unexpected so soon in the study")


Hi,



Actually the standard lab results have not been made available to us.  We hope to see them after they are prepared for the safety board.  This is clearly stated in the press release.  “As we await the lab reports.....


Please remember the protocol is strictly followed.  The primary reason for the trial and its title is 

A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors


When Dr. Menon says “The clinical trials are progressing extremely well and right on schedule,” commented Dr. Krishna Menon, Chief Scientific Officer at Cellceutix.  “As we await the lab reports, it’s very encouraging that we have not seen any of the toxic side effects that are commonly associated with chemotherapy at this point.  Many new drugs demonstrate toxicity immediately, so I interpret the information on Kevetrin™ with a great deal of optimism.  We are excited for the upcoming weeks when the next cohort, in which dosing levels will be doubled, may provide us even greater insight on what we believe is the most exciting oncologic drug in development today.”  

That is based on the minutes of the teleconference meeting with the hospital who of course have access to all records and the care givers who dose and see the patients.



We are very pleased that  the Harvard lab has now decided to do PK work.  It was actually unexpected so soon in the study. As far as the lab tests for the p21 biomarker, we have not received word on the timing of these tests.  As per the title of the study, p21 (biomarker for p53) is a secondary goal.  We dont know when they will do such.



Remember these patients have only a few months to live when they began this trial.  Now that a month has passed its nice to hear this report from the hospital.  Remember that the dose given is very low as per the clinical protocol, and dosing escalates on every future cohort.





I too am impatient.  However as the trials moves forward, all our questions will be answered.

Best regards



Leo




On Sat, Dec 1, 2012 at 11:51 AM, James Maffei , Sr. <lmaffei@roadrunner.com> wrote:

 

Hi Leo.This is probably a dumb question but I saw that 84 blood samples were just sent to the lab.Assuming they have been testing over the previous 4 weeks right along,is there anything these latest samples could reveal that earlier samples might not?

Thanks , Jim






(0)
(0)




Innovation Pharmaceuticals Inc (IPIX) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us